Welcome to our dedicated page for Neurocrine Biosciences SEC filings (Ticker: NBIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Neurocrine Biosciences’ SEC disclosures can feel like a clinical trial in itself—hundreds of pages of neurology jargon, R&D cost tables, and patent-expiry timelines bury crucial signals such as INGREZZA revenue momentum and cash runway for its congenital adrenal hyperplasia program. If you have ever asked, “Where can I find Neurocrine Biosciences’ quarterly earnings report 10-Q filing?” or “How do I track NBIX insider trading Form 4 transactions in real time?”, you know the challenge.
Stock Titan’s AI does the heavy lifting. Our engine reads every new 10-K, 10-Q, 8-K, proxy and S-8 the moment it lands on EDGAR, then translates complex language into clear takeaways. Instead of combing through footnotes, you receive concise explanations, cash-flow highlights, and instant alerts on Neurocrine Biosciences Form 4 insider transactions real-time. Key documents and what you’ll learn are grouped for fast access:
- Annual report 10-K simplified – spot INGREZZA sales trends, R&D tax credits and patent life in minutes.
- Quarterly earnings report 10-Q filing – compare sequential revenue, trial spend and liquidity ratios without crunching spreadsheets.
- 8-K material events explained – understand clinical-trial readouts or FDA updates as soon as they post.
- Executive stock transactions Form 4 – monitor buying or selling that may signal management’s conviction.
- Proxy statement executive compensation – review incentive structures tied to pipeline milestones.
Whether you need understanding Neurocrine Biosciences SEC documents with AI before the market opens or a deeper dive into NBIX earnings report filing analysis for strategy meetings, Stock Titan delivers complete, continuously updated coverage—no biotech PhD required.
A director of Neurocrine Biosciences, Inc. reported stock transactions in mid-December 2025. On December 15, 2025, the director exercised 8,276 stock options at
Neurocrine Biosciences Chief Scientific Officer reports RSU vesting and tax withholding shares
The Chief Scientific Officer of Neurocrine Biosciences, Inc. reported routine equity activity on November 29, 2025. A restricted stock unit (RSU) award converted into 4,426 shares of common stock at an exercise price of $0, increasing the executive’s directly held position to 18,129 shares before tax withholding. To cover tax obligations on the RSU vesting, the company withheld 2,248 shares at a value of $152.16 per share, leaving the executive with 15,881 shares of common stock held directly after the transactions.
The RSU was originally granted on November 29, 2021 and vested in four annual tranches: 4,425 shares on November 29, 2022, 4,425 shares on November 29, 2023, 4,426 shares on November 29, 2024, and 4,426 shares on November 29, 2025, in each case subject to the award’s terms and conditions.
Neurocrine Biosciences (NBIX) reported an insider equity transaction by a director. On 11/25/2025, the reporting person exercised a non-qualified stock option for 15,000 shares of common stock at an exercise price of
On the same date, the director disposed of 15,000 shares of common stock in an open-market sale coded "S," at a weighted average price of
Neurocrine Biosciences, Inc. (NBIX) reported an update to its senior leadership arrangements. Former Chief Medical Officer Eiry W. Roberts, M.D., who transitioned to the role of Strategic Advisor effective June 2, 2025, will continue in that advisory role for an additional 12 months. On November 21, 2025, the company and Dr. Roberts entered into an amendment to her amended and restated employment agreement to extend her employment term through December 31, 2026.
The amendment is filed as an exhibit to this report, reflecting the company’s decision to retain Dr. Roberts’ expertise in a strategic advisory capacity following the appointment of Sanjay Keswani, M.D. as Chief Medical Officer.
Neurocrine Biosciences (NBIX) reported an insider transaction. On 11/05/2025, a director exercised 18,000 non-qualified stock options at an exercise price of $47.89 per share and sold 18,000 common shares at a weighted average price of $151.8161. The sale was executed under a Rule 10b5-1 trading plan adopted on August 6, 2025.
Following these transactions, the reporting person beneficially owned 40,360 shares, held by the Rastetter Family Trust. The option was granted on May 20, 2016 and was due to expire on May 20, 2026.
Neurocrine Biosciences (NBIX) CEO and director reported Form 4 activity. On 11/01/2025, 613 shares of common stock were acquired at $0 upon RSU vesting.
On 11/04/2025, 300 shares were sold at $141.97. The filing states these mandatory sales were made to cover withholding taxes and are intended to meet Rule 10b5-1(c). After these transactions, directly held shares were 140,407, and derivative holdings (RSUs) were 1,842. Beneficial ownership includes 200 shares purchased on 02/28/2025 under the company’s ESPP.
Neurocrine Biosciences reported strong Q3 2025 results, with total revenues of $794.9 million, up from $622.1 million a year ago. Growth was driven by INGREZZA net product sales of $686.6 million and the U.S. launch of CRENESSITY contributing $98.1 million. Operating income was $239.0 million and net income reached $209.5 million, translating to diluted EPS of $2.04 versus $1.24 last year.
The company continued to invest for growth: research and development expense rose to $250.0 million and selling, general, and administrative expense to $291.6 million. Year to date, cash flows from operating activities were $394.3 million. As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $2,113.3 million, with working capital of $1,520.4 million. Neurocrine repurchased 1.8 million shares for $227.2 million during the first nine months of 2025 under its $500 million authorization and completed a $300 million accelerated repurchase begun in 2024. Shares outstanding were 99,705,698 as of October 21, 2025.
Onyia Jude, Chief Scientific Officer of Neurocrine Biosciences, reported a non-market transfer of common stock on 09/03/2025. The filing shows 1,470 shares were disposed of as a gift/charitable contribution with no cash received, and 13,703 shares remained beneficially owned after the transaction. The Form 4 was signed by an attorney-in-fact on 09/04/2025 and lists the transaction code as G(1), indicating a gift. No derivative securities were reported.
Stephen A. Sherwin, a director of Neurocrine Biosciences Inc. (NBIX), reported a non-market transfer of 1,000 shares of the company's common stock on 09/02/2025 coded as a gift (transaction code G(1)). The form shows $0 as the price because no cash was received for the gifted shares. After the transaction, Mr. Sherwin beneficially owned 12,542 shares, held directly. The filing was executed by attorney-in-fact Darin Lippoldt and dated 09/03/2025. The Form 4 discloses this change in beneficial ownership and follows Section 16 reporting requirements.
FAQ
What is the current stock price of Neurocrine Biosciences (NBIX)?
What is the market cap of Neurocrine Biosciences (NBIX)?
